AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02703974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early handwashing station
Description: A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete.
Study NCT02703974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late handwashing station
Description: A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3.
Study NCT02211833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT03143244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine group (D)
Description: Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
Study NCT02703974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late handwashing station
Description: A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3.
Study NCT03143244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac-Midazolam group (KM)
Description: Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
Study NCT03143244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Normal Saline) (C)
Description: Patients received normal saline in two sets
Study NCT02703974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: A nudge will be built in each randomly selected school and will consist of:~1. Connecting latrines to the handwashing station via paved pathways that are painted bright colors~2. Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school.
Study NCT01340339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
Study NCT01340339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
Study NCT03144076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RSBY Health Insurance
Description: RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
Study NCT03231371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
Study NCT00638547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRT Laronidase
Description: Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture
Study NCT01959581 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Movement Enhancing Device
Description: Naturalistic play activities using the hands while wearing the movement enhancing device.
Study NCT03639155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat reference tablets
Description: oral tablet
Study NCT03639155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat test tablets
Description: oral tablet
Study NCT01061294 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Advanced CustomVue™ iLASIK procedure
Study NCT01061294 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System
Study NCT02535195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger supplement
Study NCT02535195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (starch)
Study NCT01675180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information
Description: Women in the intervention group will recieve information and counseling on oral health care during pregnancy
Study NCT01675180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention
Study NCT06271096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra muscular Midazolam
Description: ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
Study NCT02703974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~* Importance of handwashing~* Method of handwashing~* Critical times of handwashing~* Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school.
Study NCT03907540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg tablet
Description: Belumosudil 200 mg tablet, development candidate
Study NCT06271096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravascular Diazepam
Description: ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
Study NCT04983147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obesity Training Based on Health Belief Model
Description: Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
Study NCT03495557 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Fascial closure with simple polydioxanone suture 2/0 stitches
Study NCT03495557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Onlay polypropylene mesh placement (MN mesh)
Study NCT02570789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patients with sunitinib or pazopanib
Description: The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
Study NCT02092870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived stem cells
Description: ASCs harvested from autologous lipoaspirate
Study NCT03907540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose
Description: test investigational medicinal product
Study NCT03907540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-KD025 200 mg capsule
Description: test investigational medicinal product
Study NCT03480555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Replenish Protein
Description: Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
Study NCT03480555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard protein
Description: Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
Study NCT00345579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014
Description: 3-dose intramuscular injection
Study NCT00345579 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB
Description: 3-dose intramuscular injection
Study NCT00345579 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix/Infanrix Penta
Description: 3-dose intramuscular injection
Study NCT02183701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02183701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan + Hydrochlorothiazide
Study NCT02183701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02183701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00345579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix/Infanrix Penta
Description: 3-dose intramuscular injection
Study NCT01002599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boussignac TM CPAP
Description: Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
Study NCT01002599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi Face Mask
Description: Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
Study NCT03323099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N-of-1
Description: Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
Study NCT03323099 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Data Tracking
Description: Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
Study NCT05247944 — intervention group
Intervention type: PROCEDURE
Intervention: Fenestrated and branched endovascular aortic repair (F-BEVAR)
Description: Fenestrated and branched endovascular aortic repair (F-BEVAR)
Study NCT05247944 — intervention group
Intervention type: PROCEDURE
Intervention: Open repair
Description: Open surgery for complex abdominal aortic aneurysm
Study NCT00541762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fat perfusion to the small intestine
Description: 1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~2. Orlistat perfused to the small intestine~3. DEXLOX as CCK-1 receptor antagonist
Study NCT01170897 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PEGPH20
Description: PEGylated Recombinant Human Hyaluronidase
Study NCT04174677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Infusion of Inebilizumab
Study NCT04174677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Infusion of VIB4920
Study NCT04174677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilzumab+VIB4920
Description: Infusion of Inebilizumab and VIB4920
Study NCT01030224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
Study NCT01030224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD9742
Description: Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
Study NCT01961830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1100 inhalation solution
Study NCT01813526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Nutritionally complete free amino acid-based medical food.
Study NCT00720616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: Norditropin 0.1 mg/day self-administered once a day subcutaneously
Study NCT01955876 — intervention group
Intervention type: DRUG
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931)
Description: Patients treated with Fosrenol in daily clinical practice.
Study NCT00286143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
Study NCT03029208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
Study NCT03029208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
Study NCT05500456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear aligners
Description: Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
Study NCT03029208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron therapy
Description: Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Study NCT03029208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron therapy
Description: Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Study NCT00951067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise, Elevation, and Compression Garment
Description: Patients will be asked to daily:~* exercise~* elevate arm~* wear an arm compression garment
Study NCT00951067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E0650 PCD with non-sequential waveform
Description: Use of an E0650 PCD with non-sequential waveform for two hours every day.
Study NCT00951067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E0651 PCD with sequential, non-gradient waveform
Description: Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
Study NCT05500456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliances
Description: Conventional wires and brackets will be used.
Study NCT00951067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E0652 PCD with sequential, gradient waveform
Description: Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
Study NCT00951067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E0652 PCD with peristaltic pulse waveform
Description: Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
Study NCT02591173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
Study NCT01018849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol 150,000 IU by mouth every 2 months for 1 year
Study NCT02591173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline will be used as the placebo comparator.
Study NCT00571909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video thorascopic splanchnicectomy (VSPL)
Description: VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
Study NCT03975673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip replacement
Description: Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
Study NCT00566969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Subjects randomized to placebo, carvedilol 25mg or 50mg
Study NCT00566969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 25 mg
Description: subjects randomized to placebo, carvedilol 25mg or 50mg
Study NCT00566969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 50 mg
Description: subjects randomized to placebo, carvedilol 25mg or 50mg
Study NCT01304017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
Study NCT01304017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
Study NCT01684306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
Study NCT01684306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
Study NCT01018849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo by mouth every 2 months for 1 year
Study NCT06364566 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemradiotherapy
Description: Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage
Study NCT06364566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Description: The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes
Study NCT02341794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
Study NCT02969473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle.